ArticlePakistan journal of medical sciences2026
Clinical efficacy of bladder hydrodistension combined with oral mirabegron and intravesical instillation in the treatment of interstitial cystitis.
Article in Pakistan journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the therapeutic efficacy of bladder hydrodistension combined with oral mirabegron and intravesical instillation in patients with interstitial cystitis(IC). Methodology: This was a retrospective study. Ninety patients diagnosed with IC at The Second Hospital of Hebei Medical University between October 2023 to October 2025 were retrospectively enrolled and randomized into two groups( Results: After six months of treatment, scores on the Pelvic Pain and Urgency/Frequency Patient Symptom Scale, Interstitial Cystitis Symptom Index, and Interstitial Cystitis Problem Index were significantly lower in the study group than in the control group( Conclusion: The combination of bladder hydrodistension, oral mirabegron, and intravesical instillation demonstrates superior clinical benefit in patients with IC. This regimen can enhance symptom relief, decrease urinary frequency, expand bladder capacity, and reduce urinary levels of EGF, NGF, and IGF-1 without a significant increase in adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.